{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-172678","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.693235+00:00","generated_at":"2026-06-13T19:14:00.651274+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Taysha regains Nasdaq independence compliance; Manning resigns, Stalfort appointed","bullets":["Paul Manning resigned from board effective June 20, 2023 to enable compliance with Nasdaq Rule 5605(b)(1); remains as non-voting observer.","Sean Stalfort appointed as independent Class I director, chair of Nominating/Governance Committee, and member of Compensation Committee.","Stalfort granted option for 43,800 shares at closing price, vesting over 36 months; annual retainer $35k plus committee fees.","Majority of board now independent; company has regained compliance with Nasdaq listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-172678","json":"https://secwatch.observer/filing/0001193125-23-172678.json","markdown":"https://secwatch.observer/filing/0001193125-23-172678.md","text":"https://secwatch.observer/filing/0001193125-23-172678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/0001193125-23-172678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/d321956d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:14:00.651274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6572cef827","claim":"Sean Stalfort was appointed as director at Taysha Gene Therapies, Inc..","evidence_excerpt":"on June 21, 2023, the Board appointed Sean Stalfort to serve as a director of the Company, effective immediately following Mr. Manning’s resignation","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/0001193125-23-172678-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"97166f78d6","claim":"Paul B. Manning resigned as director at Taysha Gene Therapies, Inc..","evidence_excerpt":"on June 20, 2023, Paul B. Manning provided notice to the Board of his decision to resign from the Board and all committees thereof","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523172678/0001193125-23-172678-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}